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Inhibition of voltage-gated Na1 currents by eleclazine
in rat atrial and ventricular myocytesRachel E. Caves, PhD,* Alexander Carpenter, MRCP,* Stéphanie C. Choisy, PhD,*
Ben Clennell, MSc,* Hongwei Cheng, PhD,* Cameron McNiff, BSc(Hons),*
Brendan Mann, BSc(Hons),* James T. Milnes, PhD,† Jules C. Hancox, DSc,*
Andrew F. James, DPhil*From the *School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, United
Kingdom, and †Xention Ltd, Cambridge, United Kingdom.BACKGROUND Atrial-ventricular differences in voltage-gated Na1
currents might be exploited for atrial-selective antiarrhythmic drug
action for the suppression of atrial fibrillation without risk of
ventricular tachyarrhythmia. Eleclazine (GS-6615) is a putative
antiarrhythmic drug with properties similar to the prototypical
atrial-selective Na1 channel blocker ranolazine that has been shown
to be safe and well tolerated in patients.
OBJECTIVE The present study investigated atrial-ventricular differ-
ences in the biophysical properties and inhibition by eleclazine of
voltage-gated Na1 currents.
METHODS The fast and late components of whole-cell voltage-
gated Na1 currents (respectively, INa and INaL) were recorded at
room temperature (w22C) from rat isolated atrial and ventricular
myocytes.
RESULTS Atrial INa activated at command potentials w5.5 mV
more negative and inactivated at conditioning potentials w7 mV
more negative than ventricular INa. There was no difference between
atrial and ventricular myocytes in the eleclazine inhibition of INaL
activated by 3 nM ATX-II (IC50s w200 nM). Eleclazine (10 mM)Address reprint requests and correspondence: Dr Andrew F. James,
School of Physiology, Pharmacology & Neuroscience, Faculty of Life Sci-
ences, University of Bristol, University Walk, Bristol, BS8 1TD, United
Kingdom. E-mail address: a.james@bristol.ac.uk.
2666-5018/© 2020 Heart Rhythm Society. Published by Elsevier Inc. This is an op
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).inhibited INa in atrial and ventricular myocytes in a use-
dependent manner consistent with preferential activated state
block. Eleclazine produced voltage-dependent instantaneous inhi-
bition in atrial and ventricular myocytes; it caused a negative shift
in voltage of half-maximal inactivation and slowed the recovery of
INa from inactivation in both cell types.
CONCLUSIONS Differences exist between rat atrial and ventricular
myocytes in the biophysical properties of INa. The more negative
voltage dependence of INa activation/inactivation in atrial myo-
cytes underlies differences between the 2 cell types in the voltage
dependence of instantaneous inhibition by eleclazine. Eleclazine
warrants further investigation as an atrial-selective antiarrhythmic
drug.
KEYWORDS Antiarrhythmic drug; Atrial myocytes; Cardiac regional
heterogeneity; INa; INa,Late; Na
1 channel blocker; Ventricular myo-
cytes
(Heart Rhythm O2 2020;1:206–214) © 2020 Heart Rhythm Society.
Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Atrial fibrillation (AF) is characterized by a rapid and irregular
electrical activation of the atria and is associated with signifi-
cant morbidity and mortality, principally through an elevated
risk of thromboembolism and ischemic stroke.1 AF is the
most common clinical arrhythmia and its prevalence can be
expected to rise with aging of the population, with consequent
increase in socioeconomic burden of the disease.2 The
elevated atrial rate during AF causes electrical and structural
remodeling that stabilizes the arrhythmia, establishing a pro-
gressive nature to the condition.1 Effective early intervention
to prevent and/or control the arrhythmia is therefore desirable.1As activation of voltage-gated Na1 channels underlies the
propagation of the cardiac action potential, and their subse-
quent inactivation initiates a refractory period, Na1 channels
represent an important target for antiarrhythmic drugs: the
combined effects of reduction in membrane excitability, con-
duction velocity (CV) slowing, and prolongation of refrac-
tory period resulting from Na1 channel block can both
suppress triggered activity and extinguish re-entrant circuits.3
Na1 channel blockers with relatively slow dissociation
kinetics are effective in the cardioversion of early-onset AF
and the maintenance of sinus rhythm.1,4 Notably, the class
Ic antiarrhythmic drugs flecainide and propafenone are rec-
ommended as a suitable “pill-in-the-pocket.”1,5
However, despite the effectiveness of class Ic antiar-
rhythmic drugs in the treatment of AF, the Cardiac
Arrhythmia Suppression Trial showed that these drugs car-
ried an increased mortality in patients with myocardial infarc-
tion, precluding their use in such individuals.6 As a result,en access article https://doi.org/10.1016/j.hroo.2020.05.006
KEY FINDINGS
- Differences exist between rat atrial and ventricular my-
ocytes in the voltage dependence of activation and
inactivation of fast Na1 current (INa).
- Eleclazine blocks INa in a use-dependent manner
consistent with preferential association with activated
states of the channel in both atrial and ventricular my-
ocytes.
- Eleclazine shows unusually rapid dissociation from the
sodium channel in both atrial and ventricular myocytes.
- The study shows an atrial-selective instantaneous inhi-
bition of INa by eleclazine.
- Eleclazine partially reverses the shortening of atrial
effective refractory period induced by the muscarinic
agonist carbachol.
Caves et al Eleclazine Inhibition of Atrial & Ventricular INa 207there has been considerable interest in alternative agents that
allow atrial-selective targeting of voltage-gated Na1 chan-
nels.7,8 In principle, atrial selectivity of action might arise
through (1) atrial-ventricular differences in the molecular,
biophysical, or pharmacological properties of voltage-gated
Na1 channels and/or (2) atrial-ventricular differences in the
resting membrane potential and action potential configura-
tion. Compared with the voltage-gated Na1 channel current
(INa) of ventricular myocytes, atrial INa inactivates and acti-
vates at more negative potentials, with more rapid onset,
and recovers more slowly from inactivation.7,9–12
The antianginal agent ranolazine (Ranexa) is a prototypic
example of a drug with atrial-selective action against voltage-
gated Na1 channels.7 Ranolazine shows use- and voltage-
dependent block of voltage-gated Na1 channels through
binding to the local anesthetic binding site within the Na1
channel vestibule and is relatively selective for the late
Na1 current (INaL).
13–16 The atrial-selective action of ranola-
zine against Na1 channels arises through a preferential block
of the activated state and trapping of the drug in the inacti-
vated state in combination with atrial-ventricular differences
in (1) the voltage dependence of INa activation and inactiva-
tion and (2) resting membrane potential and diastolic interval
(DI).7,12,16 Ranolazine suppresses the incidence of AF in
anginal patients and is suggested to be effective in pharmaco-
logical cardioversion of patients with early-onset AF and the
prevention of postoperative AF.17–20 However, at
therapeutically relevant concentrations, ranolazine also
inhibits the rapid delayed rectifier current (IKr) and delays
ventricular repolarization.21 As use of ranolazine has been
associated with cases of torsades de pointes arrhythmia,22,23
albeit rarely, an atrial-selective antiarrhythmic without effect
on IKr is desirable. It can be anticipated that selective inhibi-
tors of INaL that show preferential block of the activated state
with rapid rates of association and dissociation would also
show an atrial-selective inhibition of the fast component ofINa at higher rates.
15,16 For example, the triazolopyridine
GS-967 (now known as PRAX-330), a proof-of-concept
selective INaL inhibitor with little activity against IKr, has
been shown to have an atrial-selective action against action
potential duration, postrepolarization refractoriness, and the
maximum upstroke velocity of the action potential, although
whether the atrial-selective action of the drug extends to fast
INa itself remains unclear.
24,25 However, the low therapeutic
index of GS-967 associated with nonselective effects on a
range of neuronal Na1 channel isoforms and high brain
penetrance make it unattractive for development as an antiar-
rhythmic drug.24
In contrast, eleclazine (ELE; formerly GS-6615) is a selec-
tive INaL blocker with properties similar to ranolazine that has
been reported to be safe and well tolerated and to shorten the
QTcF interval in patients with long QT3 syndrome.
26,27 ELE
has been shown to inhibit fast INa in a use-dependent manner
consistent with preferential activated state block with little ef-
fect on IKr
27,28 and to reduce spontaneous AF in an intact
porcine model.29 The objectives of this study were to inves-
tigate atrial-ventricular differences in the properties of INa
and its inhibition by ELE in rat cardiac myocytes.Methods
Detailed methods are available in supplemental information
online.Rat cardiac myocyte isolation
Rat left ventricular and left atrial myocytes were isolated as
described previously using procedures approved by the
University of Bristol Animal Welfare and Ethics Board in
accordance with UK legislation and the Guide for the Care
and Use of Laboratory Animals.30,31Whole-cell recording of voltage-gated Na1 currents
Whole-cell Na1 currents were recorded at room temperature
using the patch clamp technique. The fast component of the
Na1 current (INa) was recorded using symmetrical internal
and external [Na1] (5 mM) whereas the late Na1 current
(INaL) was recorded using 70 mM external and 5 mM internal
[Na1] (Supplemental Table 1).Electrophysiological recordings from whole hearts
Atrial effective refractory period (ERP) and CV were
measured in Langendorff-perfused rat hearts as described
previously.32Eleclazine
ELE (3,4-dihydrobenz-[1,4]oxazepin-5(2H)-one) was a gift
of Dr James T. Milnes (Xention Ltd, Cambridge, UK).















































































Figure 1 Atrial-ventricular differences in fast Na1 current (INa) density–voltage relations.A, B: Representative current traces recorded from an atrial (A) and a
ventricular myocyte (B) on depolarization to a range of voltages. Arrows indicate zero current level. Insert shows voltage pulse protocol. Residual uncompensated
capacitative transients have been blanked for clarity.C:Mean INa density–voltage relations for atrial (filled circles, n5 10) and ventricular (open circles, n5 10)
myocytes. Solid lines represent fits to Supplemental Equation 1. Data were significantly different by both cell type (P , .05) and voltage (P, .0001) with sig-
nificant interaction (P, .0001; 2-way repeated measures analysis of variance). **P, .01; ****P, .0001 vs ventricular; Bonferroni post hoc test. D: Voltage
dependence of time-to-peak (TTP) INa for atrial (filled circles, n5 10) and ventricular (open circles, n5 10) myocytes. The membrane time constants were 0.161
6 0.021 ms for atrial myocytes (n 5 10) and 0.314 6 0.025 ms for ventricular cells (n 5 10; P 5 .00016, unpaired Student t test).
208 Heart Rhythm O2, Vol 1, No 3, August 2020Statistics
Data are presented as the mean6 standard error of the mean.
The limit of statistical confidence was P, .05. Curve fitting
was performed by nonlinear least squares using Igor Pro v6
(Wavemetrics Inc, Tigard, OR).Results
Depolarizing pulses activated inward currents with rapid ki-
netics of activation and inactivation typical of INa in both
atrial and ventricular myocytes (Figure 1A and B). The cur-
rents of both cell types showed a U-shaped current density–
voltage relation with a zero current potential close to zero
mV, consistent with their Na1 selectivity (Figure 1C). How-
ever, INa from atrial myocytes activated at more negative
voltages than ventricular INa, with measurable inward cur-
rents being evident from voltages of -60 mV and positive
and reaching a maximum at approximately -40 mV in atrial
cells, whereas INa in ventricular myocytes were activated
from -50 mV and reached a maximum at w-30 mV
(Figure 1C). The whole-cell capacitance of atrial myocytes
was significantly lower than that of ventricular myocytes
(atrial 47.6 6 2.5 pF, n 5 10; ventricular 85.6 6 3.7 pF, n
5 10; P , .00001), consistent with their smaller size. The
current density–voltage relations of each cell type were fittedby a modified Boltzmann relation (Supplemental Equation 1)
and the more negative voltage dependence of activation of
atrial INa was reflected in a mean half-maximal voltage of
activation (Vhalf,act) approximately 5.5 mV more negative
than that of ventricular INa (P , .05; Supplemental
Table 2). There were no significant differences between atrial
and ventricular myocytes in the slope factors or maximal INa
conductance density (Supplemental Table 2). Atrial INa
showed shorter time-to-peak current values than ventricular
currents, suggesting more rapid activation of atrial voltage-
gated Na1 channels (Figure 1D).
Conditioning pulses of 1.5 seconds from -150 mV to -50
mV revealed voltage-dependent inactivation of INa in both
atrial and ventricular myocytes (Figure 2). Currents were
maximal from conditioning potentials of -130 mV but
showed voltage-dependent inactivation at more positive po-
tentials. The rate of onset of INa inactivation was examined
by fitting a single decaying exponential relation
(Supplemental Equation 2) to the currents activated from a
conditioning potential of -130 mV (see inserts to Figure 2A
and B). There was no difference in the onset of INa inactiva-
tion between atrial and ventricular myocytes (t: atrial, 1.616
0.01 ms, n5 11; ventricular, 1.596 0.01 ms, n5 12). Atrial
INa inactivated at more negative voltages than the current in
ventricular cells, with significant differences evident between
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Figure 2 Atrial-ventricular differences in steady-state voltage-dependent
inactivation of fast Na1 current (INa). A, B: Representative current traces re-
corded from an atrial (A) and a ventricular myocyte (B) on depolarization to
-30 mV following conditioning at a range of voltages. Conditioning potential
(Vcond) for 2 of the traces indicated. Arrows indicate zero current level. In-
serts show voltage pulse protocol and current trace elicited from a Vcond of
-130 mV on an expanded time scale. Dashed lines represent fits to
Supplemental Equation 2. Supplemental Equation 2 showed a better
goodness-of-fit than Supplemental Equation 3 according to the Akaike Infor-
mation Criterion. Residual uncompensated capacitative transients have been
blanked for clarity. C:Mean INa steady-state voltage-dependent inactivation
curves for atrial (filled circles, n5 11) and ventricular (open circles, n5 12)
myocytes. INa were normalized to the maximum inward current amplitude.
Dashed lines represent fits to Supplemental Equation 4. Data were signifi-
cantly different by both cell type (P , .001) and voltage (P , .0001) with
significant interaction (P, .0001; 2-way repeated measures analysis of vari-
ance). ***P, .001; ****P, .0001 vs ventricular; Bonferroni post hoc test.
Figure 3 Eleclazine inhibition of the late Na1 current (INaL) in atrial and
ventricular myocytes. A, B: Representative current traces recorded from an
atrial (A) and a ventricular myocyte (B) on depolarization to -20 mV in con-
trol (control), 10 mM tetrodotoxin (TTX), 3 nM sea anemone toxin (ATX-II),
and eleclazine (ELE, 300 nM). C: Concentration dependence of INaL inhibi-
tion by ELE. Currents measured at 400 ms were normalized to the corre-
sponding activated current in the presence of ATX-II alone and plotted
against the corresponding concentration of ELE. Each data point represents
the mean (6 standard error of the mean) of data from 5 cells and each cell was
exposed to a single concentration of ELE. Curves represent fits to
Supplemental Equation 5.
Caves et al Eleclazine Inhibition of Atrial & Ventricular INa 209the 2 cell types in the range from -100 mV to -80 mV
(Figure 2C). The voltage dependence of inactivation was
fitted by a Boltzmann relation (Supplemental Equation 4)
and the mean half-maximal voltage of inactivation (Vhalf,inact)
of atrial cells wasw7 mVmore negative than that of ventric-
ular myocytes (Supplemental Table 2).
Representative recordings of late Na1 currents (INaL) acti-
vated on depolarization to -20 mV from atrial (Figure 3A) and
ventricular (Figure 3B) myocytes are shown in Figure 3. Un-
der control conditions, while there was no significant differ-
ence in the amplitude of INaL between the 2 cell types (atrial
-20 6 3.2 pA, n 5 25; ventricular -23 6 6.0 pA, n 5 25),
the atrial INaL density normalized to capacitance as an index
of membrane surface area was almost 2-fold greater in atrialthan in ventricular myocytes (atrial -0.37 6 0.06 pA/pF,
ventricular -0.19 6 0.07 pA/pF; P , .05). Superfusion of
the cells with 3 nM sea anemone toxin (ATX-II) caused a
marked increase in INaL in both atrial and ventricular myocytes
(cf. Figure 3A and B), although there was no difference
between the cell types in INaL density in the presence of the
sea anemone toxin (atrial -12.96 1.2 pA/pF, n5 25; ventric-
ular -13.8 6 1.3 pA/pF, n 5 25). The ATX-II-activated INaL
was inhibited by ELE in a concentration-dependent manner
in both atrial and ventricular myocytes (Figure 3C). There
was no difference between atrial and ventricular myocytes in
the concentrations of half-maximal current inhibition (IC50)
by ELE (atrial 217.2 nM, ventricular 179.9 nM;
Supplemental Table 3).
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Figure 4 Use-dependent inhibition of fast Na1 current (INa) by eleclazine (ELE, 10 mM).A, B:Mean normalized current amplitudes recorded by a series of 40
pulses to -30 mV at diastolic intervals (DI) of 110 (circles) and 40 ms (triangles) in atrial (A, filled symbols, n5 12) and ventricular myocytes (B, open symbols)
from a holding potential of -120 mV in the presence of ELE. Currents were normalized to the currents elicited in the absence of ELE by the corresponding pulse
number according to Supplemental Equation 6. Solid lines in A and B represent fits to Supplemental Equation 7.C:Themean percentage use-dependent inhibition
(Supplemental Equation 8) at DI of 110 and 40 ms from atrial (filled columns) and ventricular (open columns) myocytes (data and sample sizes correspond to A
and B). Use-dependent inhibition was significantly different by DI (P, .0001) but not by cell type (P5 .7591). ****P, .0001; Bonferroni post hoc test vs DI
110 ms in the same cell type.D: The effect of holding potential (HP) on mean percentage instantaneous inhibition (Supplemental Equation 9) by ELE. Data show
mean inhibition on the first pulse to -30.mV at a DI of 110 ms in atrial (filled columns: HP5 -120 mV, n5 12 and HP5 -100 mV, n5 8) and ventricular (open
columns, HP 5 -120 mV, n 5 9 and HP 5 -100 mV, n 5 9) myocytes. ****P , .0001, 2-way analysis of variance. ##P , .01; Student unpaired t test.
210 Heart Rhythm O2, Vol 1, No 3, August 2020The use-dependent interaction of ELE (10 mM) with
voltage-gated Na1 channels was investigated in atrial and
ventricular myocytes by examining the effects of shortening
of DI on the degree of inhibition of INa during fixed trains of
40 consecutive pulses of 20 ms duration to -30 mV from a
holding potential (HP) of -120 mV (Figure 4). The effects
of DI of 110 ms and 40 ms were examined in each cell. If
the drug interaction with the resting channel is weak, then
ELE will tend to dissociate during the DI. Reduction of DI
can thus be expected to lead to accumulation of inhibition
as the time for unbinding becomes abbreviated. ELE
(10 mM) inhibited INa in a use-dependent manner, the level
of inhibition accumulating over the 40 consecutive pulses,
the inhibition being greater at the shorter DI (Figure 4A
and B). The rate of accumulation of inhibition by ELE was
not significantly affected by DI in either atrial or ventricular
myocytes and there was no difference between the 2 cell
types in the rate of accumulation of inhibition
(Supplemental Table 4). The use-dependent inhibition by
ELE, quantified as the difference in percentage inhibition be-
tween the first and the 40th pulse, was not different betweenatrial and ventricular cells (Figure 4C). However, instanta-
neous inhibition of INa by ELE on the first pulse was evident
in atrial but not in ventricular myocytes from the HP of -120
mV (Figure 4D). To examine the voltage dependence of the
inhibition of INa by ELE in the 2 cell types, the fixed train pro-
tocol was run from an HP of -100 mV in separate cells
(Supplemental Figure 1). There was no difference between
atrial and ventricular myocytes in the use-dependent inhibi-
tion at -100 mV (Supplemental Figure 1C). However, the
instantaneous inhibition by ELE was markedly increased
by depolarization of the HP to -100 mV in both cell types
(Figure 4D). In contrast to the data at -120 mV, there was
no difference between atrial and ventricular myocytes in
the instantaneous inhibition of INa at -100mV. Consequently,
although the total inhibition, as calculated according to
Supplemental Equation 10, by ELE evident on the final pulse
at either DI was greater in atrial than in ventricular myocytes
at -120 mV, there was no difference in total inhibition
between the 2 cell types at -100 mV (Supplemental
Figure 2). To examine whether ELE interacts strongly with
inactivated states of the Na1 channel, we followed the
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Figure 5 Effect of pulse duration on the use-dependent inhibition by eleclazine (ELE). Mean normalized current amplitudes recorded by a series of 40 pulses to
-30 mV at diastolic intervals of 110 ms in A: atrial myocytes (filled circles, n5 5) and B: ventricular myocytes (open circles, n5 5) from a holding potential of
-120 mV in the presence of 10 mMELE. Gray-filled circles data from Figure 4 with pulse durations of 20 ms are shown for comparison (atrial n5 12; ventricular
n 5 9). Currents were normalized to the currents elicited in the absence of ELE by the corresponding pulse number.
Caves et al Eleclazine Inhibition of Atrial & Ventricular INa 211methodology of Zygmunt and colleagues16 and examined the
effect on use-dependent inhibition of prolonging the depola-
rizing pulse to 200 ms at a constant DI of 110 ms (Figure 5).
Prolongation of the depolarizing pulse from 20 to 200 ms can
be expected to have increased the proportion of channels in
the inactivated state at the end of the pulse.16 The total inhi-
bition was unaffected by pulse duration in either atrial or ven-
tricular myocytes (2-way analysis of variance [ANOVA]),
consistent with preferential association of ELE with activated



















Figure 6 Effect of eleclazine (ELE) on half-maximal voltage of steady-
state inactivation. Data shown are the mean changes in half-maximal voltage
of inactivation (Vhalf,inact) caused by 10 mM ELE for atrial (filled column,
n 5 9) and ventricular (open column, n 5 9) myocytes. Hatched columns
show corresponding time-matched controls in the absence of ELE for 8 atrial
and 9 ventricular myocytes. **P , .01; ***P , .001; 2-way analysis of
variance with Bonferroni post hoc test.The effect of ELE on steady-state inactivation was exam-
ined as the ELE-induced shift in the half-maximal voltage of
inactivation (DVhalf,inact) in atrial and ventricular myocytes
(Figure 6). In both cell types, treatment with ELE was asso-
ciated with a negative shift in Vhalf,inact of w3.5 mV
(Figure 6). Time-matched control experiments showed a
time-dependent shift in Vhalf,inact in atrial and ventricular my-
ocytes, with no significant difference between the cell types
in the magnitude of the shift (Figure 6). Although the
ELE-induced shift in Vhalf,inact was significantly greater
than the time-matched control in both atrial and ventricular
myocytes, there was no significant difference between cell
types in the drug-induced shift in Vhalf,inact.
In both atrial and ventricular myocytes, INa recovered
from inactivation with a biexponential time course, with a
fast time constant (tf) of 5–30 ms and a slow time constant
(ts) of 100–220 ms (Figure 7A). Under control conditions,
the recovery from inactivation was slower in atrial than in
ventricular myocytes (P , .0001, 3-way ANOVA;
Supplemental Table 5). Although the mean fast and slow
time constants were larger (ie, slower) in atrial than in ven-
tricular cells, this did not achieve the level of statistical con-
fidence (Figure 7B). On the other hand, although the fast
component of recovery predominated in both cell types, the
contribution of the fast component was less in atrial than in
ventricular myocytes (Figure 7C). The recovery from inacti-
vation was slowed by ELE in both cell types. The slowing of
the mean fast time constant was greater in atrial (w65% in-
crease) than in ventricular (w40% increase) myocytes,
whereas there was little difference between atrial and ventric-
ular myocytes in the effect of ELE on the slow time constant
(40%–45% increase in both cell types) (Figure 7B). ELE
decreased the contribution of the fast component to recovery
to 20%–25% in both cell types, so that themean time course of
recovery from inactivation of INawas indistinguishable in the 2
cell types in the presence of the drug (Figure 7A and C). There


















































































Figure 7 Effect of eleclazine (ELE) on fast Na1 current (INa) recovery from inactivation. A: Recovery of INa from inactivation in atrial (filled symbols, n5 7)
and ventricular (open symbols, n5 7) myocytes. Dashed lines represent fits to Supplemental Equation 11. The holding potential during recovery was -120 mV.
B: Fitted fast (left-hand panel) and slow (right-hand panel) time constants in control and in the presence of 10 mM ELE for atrial (filled columns) and ventricular
(open columns) myocytes. *P, .05; ***P, .001; ****, P, .0001; 2-way repeated measures analysis of variance (ANOVA) with Bonferroni post hoc test vs
control. C:Mean amplitude of fast component in control and in the presence of 10 mM ELE for atrial (filled columns) and ventricular (open columns) myocytes.
****P , .0001; 2-way repeated measures ANOVA with Bonferroni post hoc test vs control.
212 Heart Rhythm O2, Vol 1, No 3, August 2020wasno significant differencebetween atrial and ventricularmy-
ocytes in the rates of recovery from the drug-bound state
(Figure 8). In both atrial and ventricular myocytes, the dissoci-
ation of ELE occurred in 2 phases; a fast phase with time con-
stant (tf) w2.5 ms and a slow phase with ts w180 ms
(Supplemental Table 6). The time constants of dissociation
did not differ between atrial and ventricular myocytes.
ELE was found to prolong the left atrial ERP in the pres-
ence of the muscarinic agonist carbachol (CCh) in
Langendorff-perfused rat hearts (Supplemental Figure 3A).
Perfusion with CCh (0.5–0.75 mM) shortened ERP by
w56% (P , .01). Subsequent perfusion with ELE (1 mM)






















Figure 8 The time course of recovery from eleclazine binding. Data were
calculated from the data shown in Figure 7A using Supplemental Equation
12. Filled circles, atrial myocytes (n5 7); open circles, ventricular myocytes
(n 5 7). Solid lines represent fits to Supplemental Equation 11. Fits were
constrained to go to 0 at time5 0.0001 second. Fitted parameters are shown
in Supplemental Table 6.ERP to w60% of the control value (P , .05). On the other
hand, neither CCh nor ELE had significant effect on CV
(Supplemental Figure 3B). Taken together, these data are
consistent with inhibition of atrial INa by ELE.Discussion
Atrial-ventricular differences in INa
Clear atrial-ventricular differences were found in the bio-
physical properties of rat cardiac voltage-gated Na1 cur-
rents: atrial INa was activated at command potentials
w5.5 mV more negative and inactivated at conditioning po-
tentials w7 mV more negative than ventricular INa, the acti-
vation time-to-peak INa following depolarization to voltages
of -50 to -30 mV was also shorter in atrial than in ventric-
ular myocytes, and the recovery of INa from inactivation
was significantly slower in atrial than in ventricular myo-
cytes. In these respects, the differences in INa between rat
atrial and ventricular cells in the present study were similar
to those reported previously in cardiac myocytes from
various species.7,9–12 On the other hand, in contrast to
previous reports from the dog, guinea pig, and rabbit
demonstrating greater INa density in atrial compared to
ventricular myocytes, there was no difference in INa density
between the 2 cell types in the present study.7,9,12 Under control
conditions, the density of INaL was greater in atrial than in ven-
tricular myocytes. Atrial-ventricular differences in the inhibition
of INa by ELE were also evident: (1) in addition to marked use-
dependent inhibition that was not significantly different between
the 2 cell types, ELE caused an instantaneous inhibition of INa in
atrial andventricularmyocytes thatwasdependent onmembrane
potential, and consequently arose at more negative membrane
potentials in atrial myocytes than in ventricular myocytes; and
(2) there was an atrial-selective slowing of the fast time constant
of recovery from inactivation. To the best of our knowledge, this
represents not only thefirst report of atrial-ventricular differences
in the effects of ELE on INa from any species, but the first report
of atrial-ventricular differences in inhibition of peak INa by any
INaL inhibitor with rapid kinetics other than ranolazine.
Caves et al Eleclazine Inhibition of Atrial & Ventricular INa 213Consistentwith inhibition of peak INa, ELEpartially reversed the
shortening in atrial ERP induced by themuscarinic agonist CCh,
indicating an atrial antiarrhythmic action of the drug. On the
other hand, it is unclear whether the effect of ELE was atrial-
selective.
Mechanism of eleclazine inhibition
ELE has been shown to block cardiac Na1 channels with
unusually rapid kinetics, interacting with the local anes-
thetic binding site and showing marked selectivity for
INaL relative to fast INa.
28 The present study demonstrates
that there was no difference between atrial and ventricular
myocytes in the concentration-dependent inhibition of
ATX-II-activated INaL by ELE, indicating similar affinity
of ELE for atrial and ventricular Na1 channels. Our data
are consistent with the inhibition of INaL by ELE via
open channel block, as suggested in previous reports.26–29
The inhibition of both INa and INaL by ELE has been
shown to be voltage-dependent so that the IC50s for inhi-
bition of the ATX-II-activated INaL in atrial and ventricular
myocytes in the present study (217 nM and 180 nM,
respectively) were comparable with the value reported pre-
viously in rabbit ventricular myocytes at a corresponding
HP of -80 mV (260 nM).27 Consistent with previous re-
ports on recordings of fast INa from rabbit ventricular my-
ocytes and recombinant human Nav1.5 channels,
27,28 10
mM ELE produced significant use-dependent inhibition,
with little difference between atrial and ventricular myo-
cytes. The rates of accumulation of INa inhibition evident
during the repeated pulse protocol in the present study
(Figure 4) were very much faster than those reported pre-
viously for ranolazine in canine and rabbit cardiac myo-
cytes using similar pulse widths, DI, and numbers of
pulses, consistent with the unusually rapid kinetics of
ELE.12,16 Though therapeutically effective doses of ELE
produce plasma concentrations of w0.5 mM, ELE is high-
ly lipophilic (logP w4.35) and accumulates at higher con-
centrations in cardiac tissue.33 Thus, it is conceivable that
treatment with ELE would affect fast INa, particularly at
higher rates during tachyarrhythmias.
The accentuation of use-dependent inhibition of fast INa at
shorter diastolic intervals in the present study reflected incom-
plete recovery from block during the diastolic interval when
the channels tend to return to the resting state. The data are
consistent with preferential interaction of ELE with activated
states of both atrial and ventricular Na1 channels. Increasing
the duration of the depolarizing pulse had no effect on the total
inhibition by ELE, indicating only weak interaction of the
drug with the inactivated state of the channel in either cell
type. In the present study, the dissociation of the drug from
Na1 channels was exceptionally rapid: dissociation of the
drug followed a biexponential time course with time constants
ofw2.5ms andw180ms, with no appreciable differences be-
tween atrial and ventricular myocytes. The value of the slow
time constant of dissociation was similar to that of the slow
component of recovery from inactivation (ts w130 ms in
both cell types), consistent with trapping of the drug by theinactivation gate impeding dissociation of ELE from the chan-
nel. The degree of instantaneous inhibition by ELE in atrial
and ventricular myocytes at an HP of -100 mV, at which there
was very little INa activation in either cell type, was striking.
From an HP of -120 mV, the instantaneous inhibition of INa
was markedly reduced in both cell types, becoming negligible
in ventricular myocytes. Although a hydrophobic pathway for
access of neutral drugs to the local anesthetic binding site of
Na1 channels has been suggested, the relatively large size of
ELE (molecular weightw415.4 g.mol-1), comparable to rano-
lazine, argues against significant access via that route.15,34 On
the other hand, overlap in the voltage dependence of steady-
state activation and inactivation will result in a small, but
nevertheless significant, window current at negative voltages
(Supplemental Figure 4). The instantaneous inhibition in atrial
myocytes at -120 mV therefore likely results from the small
proportion of channels activated at the HP. Thus, the differ-
ence between atrial and ventricular myocytes in instantaneous
inhibition likely reflects differences in the voltage dependence
of activation of the window current in the 2 cell types.
Given the use-dependent action of ELE, its preference
for the activated state, and rapid dissociation from the
noninactivated sodium channel, the less negative resting
membrane potential, differences in action potential
morphology, and consequent shorter diastolic interval of
atrial relative to ventricular myocytes may contribute to an
atrial-selective action of ELE.7,16Conclusions
Although there was no evidence of any difference between
atrial and ventricular INa (or INaL) in the kinetics of drug bind-
ing/dissociation, the more negative voltage dependence of INa
activation and inactivation underlies an atrial-selective instan-
taneous inhibition of INa by ELE. The present study provides
further evidence to support the contention that INaL inhibitors
have differential effects on atrial and ventricular INa. However,
additional future investigation is now required to establish
whether the actions of ELE on atrial INa form the basis for an
atrial-selective antiarrhythmic action. Chamber-specific hu-
man induced pluripotent stem cell–derived cardiomyocytes
(hiPSC-CM) represent an attractive potential human model
for validation of the atrial-selective action of antiarrhythmic
drugs. However, though differentiation protocols are available
to drive hiPSCs towards an atrial- or ventricular-like pheno-
type, iPSC-CM express both fetal (exon 6A) and adult (exon
6) isoforms of SCN5A, leaving the relevance of the data
from studies using these models open to question.35 On the
other hand, studies in a pertinent model of AF would provide
important evidence regarding the potential for an atrial-
selective antiarrhythmic action of ELE.Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hroo.2020.
05.006.
214 Heart Rhythm O2, Vol 1, No 3, August 2020Funding Sources
The study was supported by project grants from the British
Heart Foundation (BHF PG/15/55/31568 and PG/16/71/
32301). Alexander Carpenter was funded by a Clinical
Research Training Fellowship from the UK Medical
Research Council (MR/S021299/1).Disclosures
Dr James T. Milnes was an employee of Xention Ltd, a bio-
pharmaceutical company specializing in the discovery and
development of ion channel modulating drugs. None of the
other authors have any conflicts of interest.References
1. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial
fibrillation: The Task Force for the Management of Atrial Fibrillation of the Eu-
ropean Society of Cardiology (ESC). Eur Heart J 2010;31:2369–2429.
2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial
fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534–1539.
3. Carmeliet E, Vereecke J. Cardiac Cellular Electrophysiology, 1st ed. New York:
Kluwer Academic Publishers; 2002.
4. Lafuente-Lafuente C, Valembois L, Bergmann J-F, Belmin J. Antiarrhythmics for
maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Data-
base Sys Rev 2015;3:CD005049.
5. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial
fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004;
351:2384–2391.
6. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients
receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781–788.
7. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C.
Atrium-selective sodium channel block as a strategy for suppression of atrial
fibrillation: differences in sodium channel inactivation between atria and ventri-
cles and the role of ranolazine. Circulation 2007;116:1449–1457.
8. Hancox JC, James AF, Marrion NV, Zhang H, Thomas D. Novel ion channel tar-
gets in atrial fibrillation. Exp Opin Ther Targets 2016;20:947–958.
9. Li G-R, Lau C-P, Shrier A. Heterogeneity of sodium current in atrial vs epicardial
ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol 2002;
34:1185–1194.
10. Chen K-H, Xu X-H, Sun H-Y, et al. Distinctive property and pharmacology of
voltage-gated sodium current in rat atrial vs ventricular myocytes. Heart Rhythm
2016;13:762–770.
11. Suzuki T, Morishima M, Kato S, Ueda N, Honjo H, Kamiya K. Atrial selectivity in
Na1 channel blockade by acute amiodarone. Cardiovasc Res 2013;98:136–144.
12. Caves RE, Cheng H, Choisy SC, et al. Atrial-ventricular differences in rabbit car-
diac voltage-gated Na1 currents: basis for atrial-selective block by ranolazine.
Heart Rhythm 2017;14:1657–1664.
13. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of
LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol
2006;148:16–24.
14. Rajamani S, El-Bizri N, Shryock JC, Makielski JC, Belardinelli L. Use-dependent
block of cardiac late Na1 current by ranolazine. Heart Rhythm 2009;
6:1625–1631.
15. Nesterenko VV, Zygmunt AC, Rajamani S, Belardinelli L, Antzelevitch C.Mech-
anisms of atrial-selective block of Na1 channels by ranolazine: II. Insights from a
mathematical model. Am J Physiol 2011;301:H1615–H1624.16. Zygmunt AC, Nesterenko VV, Rajamani S, et al. Mechanisms of atrial-selective
block of Na1 channels by ranolazine: I. Experimental analysis of the use-
dependent block. Am J Physiol 2011;301:H1606–H1614.
17. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to
convert new or paroxysmal atrial fibrillation: a review of experience with impli-
cations for possible "pill in the pocket" approach to atrial fibrillation. Indian Pac-
ing Electrophysiol J 2009;9:260–267.
18. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical
cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Elec-
trophysiol 2012;35:302–307.
19. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent
with novel electrophysiological properties, on the incidence of arrhythmias in pa-
tients with non–ST-segment–elevation acute coronary syndrome: results from the
Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation
Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36
(MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;
116:1647–1652.
20. Patel N, Kluger J. Ranolazine for prevention of atrial fibrillation after cardiac sur-
gery: a systematic review. Cureus 2018;10:e2584.
21. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of
ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation
2004;110:904–910.
22. Tarapues M, Cereza G, Arellano AL, Montane E, Figueras A. Serious QT interval
prolongation with ranolazine and amiodarone. Int J Cardiol 2014;172:e60–e61.
23. Liu Z, Williams RB, Rosen BD. The potential contribution of ranolazine to
Torsade de Pointe. J Cardiovasc Dis Res 2013;4:187–190.
24. Koltun DO, Parkhill EQ, Elzein E, et al. Discovery of triazolopyridine GS-
458967, a late sodium current inhibitor (Late INai) of the cardiac NaV1 5 channel
with improved efficacy and potency relative to ranolazine. BioorgMed Chem Lett
2016;26:3202–3206.
25. Burashnikov A, Diego JMD, Goodrow RJ, Belardinelli L, Antzelevitch C. Atria
are more sensitive than ventricles to GS-458967-induced inhibition of late sodium
current. J Cardiovasc Pharmacol Ther 2015;20:501–508.
26. Zablocki JA, Elzein E, LiX, et al. Discovery of dihydrobenzoxazepinone (GS-6615)
late sodium current inhibitor (late INai), a phase II agent with demonstrated preclin-
ical antiischemic and antiarrhythmic properties. J Med Chem 2016;59:9005–9017.
27. Rajamani S, Liu G, El-Bizri N, et al. The novel late Na1 current inhibitor, GS-
6615 (eleclazine) and its antiarrhythmic effects in rabbit isolated heart prepara-
tions. Br J Pharmacol 2016;173:3088–3098.
28. ElBizri N, Xie C, Liu L, et al. Eleclazine exhibits enhanced selectivity for long QT
syndrome type 3–associated late Na1 current. Heart Rhythm 2018;15:277–286.
29. Fuller H, Justo F, Nearing BD, et al. Eleclazine, a new selective cardiac late so-
dium current inhibitor, confers concurrent protection against autonomically
induced atrial premature beats, repolarization alternans and heterogeneity, and
atrial fibrillation in an intact porcine model. Heart Rhythm 2016;13:1679–1686.
30. Bryant S, Kimura TE, Kong CHT, et al. Stimulation of ICa by basal PKA activity
is facilitated by caveolin-3 in cardiac ventricular myocytes. J Mol Cell Cardiol
2014;68:47–55.
31. Garger JC, Barbee RW, Bielitzki JT, et al. Guide for the Care and Use of Labo-
ratory Animals, 8th ed. Washington DC: The National Academies Press; 2011.
32. Kim S-J, Choisy SCM, Barman P, et al. Atrial remodeling and the substrate for
atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophy-
siol 2011;4:761–769.
33. Bacic D, Carneiro JS, Bento AA, et al. Eleclazine, an inhibitor of the cardiac late
sodium current, is superior to flecainide in suppressing catecholamine-induced
ventricular tachycardia and T-wave alternans in an intact porcine model. Heart
Rhythm 2017;14:448–454.
34. Martin LJ, Corry B. Locating the route of entry and binding sites of benzocaine
and phenytoin in a bacterial voltage gated sodium channel. PLoS Comput Biol
2014;10:e1003688.
35. Goodrow RJ, Desai S, Treat JA, et al. Biophysical comparison of sodium currents
in native cardiac myocytes and human induced pluripotent stem cell-derived car-
diomyocytes. J Pharmacol Toxicol Meth 2018;90:19–30.
